• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
COVID-19 vaccines: Global challenges and prospects forum recommendations.新冠疫苗:全球挑战与前景论坛建议
Int J Infect Dis. 2021 Apr;105:448-451. doi: 10.1016/j.ijid.2021.02.093. Epub 2021 Feb 27.
2
COVID-19 vaccines: concerns beyond protective efficacy and safety.COVID-19 疫苗:除了保护效力和安全性之外的关注点。
Expert Rev Vaccines. 2021 Aug;20(8):1013-1025. doi: 10.1080/14760584.2021.1949293. Epub 2021 Jul 5.
3
SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?在研的 SARS-CoV-2 疫苗:我们处于什么阶段?
Adv Drug Deliv Rev. 2021 May;172:314-338. doi: 10.1016/j.addr.2021.01.014. Epub 2021 Jan 20.
4
Who Will Pay for the COVID-19 Vaccines for Africa?非洲的 COVID-19 疫苗将由谁来买单?
Am J Trop Med Hyg. 2021 Jan 7;104(3):794-796. doi: 10.4269/ajtmh.20-1506.
5
Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.基于 SARS-CoV-2 的免疫原性结构蛋白、宿主免疫反应和群体免疫的 COVID-19 疫苗开发的新见解。
Cells. 2021 Oct 29;10(11):2949. doi: 10.3390/cells10112949.
6
Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.辉瑞/生物科技和牛津/阿斯利康疫苗对沙特阿拉伯全国疫苗接种运动中真实环境下 COVID-19 发病率和死亡率的影响。
Eur Rev Med Pharmacol Sci. 2021 Nov;25(22):7185-7191. doi: 10.26355/eurrev_202111_27271.
7
Challenges and prospects of COVID-19 vaccine development based on the progress made in SARS and MERS vaccine development.基于 SARS 和 MERS 疫苗研发进展的 COVID-19 疫苗研发的挑战与前景。
Transbound Emerg Dis. 2021 May;68(3):1111-1124. doi: 10.1111/tbed.13804. Epub 2020 Sep 23.
8
COVID-19 vaccines: rapid development, implications, challenges and future prospects.COVID-19 疫苗:快速发展、影响、挑战与未来前景。
Hum Cell. 2021 May;34(3):711-733. doi: 10.1007/s13577-021-00512-4. Epub 2021 Mar 7.
9
COVID-19 vaccine access in Africa: Global distribution, vaccine platforms, and challenges ahead.非洲的 COVID-19 疫苗获取:全球分配、疫苗平台和未来挑战。
Immunity. 2021 Jul 13;54(7):1353-1362. doi: 10.1016/j.immuni.2021.06.017.
10
Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine.临床认可基于纳米技术的 SARS-CoV-2 mRNA 疫苗:对转化纳米医学的影响。
Drug Deliv Transl Res. 2021 Aug;11(4):1309-1315. doi: 10.1007/s13346-021-00911-y. Epub 2021 Jan 29.

引用本文的文献

1
Persistence of Anti-SARS-CoV-2 Spike IgG Antibodies Following COVID-19 Vaccines.新冠疫苗接种后抗SARS-CoV-2刺突蛋白IgG抗体的持久性
Infect Drug Resist. 2022 Jul 29;15:4127-4136. doi: 10.2147/IDR.S362848. eCollection 2022.
2
Aquaculture Production and Value Chains in the COVID-19 Pandemic.新冠疫情期间的水产养殖生产和价值链
Curr Environ Health Rep. 2022 Sep;9(3):423-435. doi: 10.1007/s40572-022-00364-6. Epub 2022 Jun 17.
3
COVID-19 Recovery Patterns Across Alpha (B.1.1.7) and Delta (B.1.617.2) Variants of SARS-CoV-2.COVID-19 康复模式在 SARS-CoV-2 的 Alpha(B.1.1.7)和 Delta(B.1.617.2)变异株中的表现。
Front Immunol. 2022 Feb 14;13:812606. doi: 10.3389/fimmu.2022.812606. eCollection 2022.
4
Antibody response to the first dose of AZD1222 vaccine in COVID-19 convalescent and uninfected individuals in Bangladesh.孟加拉国 COVID-19 康复者和未感染者对 AZD1222 疫苗首剂的抗体反应。
Expert Rev Vaccines. 2021 Dec;20(12):1651-1660. doi: 10.1080/14760584.2021.1977630. Epub 2021 Sep 15.
5
COVID-19 Pandemic and Equal Access to Vaccines.新冠疫情与疫苗的平等可及性
Vaccines (Basel). 2021 May 21;9(6):538. doi: 10.3390/vaccines9060538.
6
An Architecture for Reliable Transportation of Delicate Goods.可靠运输易碎品的架构。
Sensors (Basel). 2021 Apr 9;21(8):2645. doi: 10.3390/s21082645.

本文引用的文献

1
COVID-19 vaccines: where we stand and challenges ahead.COVID-19 疫苗:我们的现状和未来的挑战。
Cell Death Differ. 2021 Feb;28(2):626-639. doi: 10.1038/s41418-020-00720-9. Epub 2021 Jan 21.
2
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults.《 老年人中新型冠状病毒 mRNA-1273 疫苗的安全性和免疫原性》
N Engl J Med. 2020 Dec 17;383(25):2427-2438. doi: 10.1056/NEJMoa2028436. Epub 2020 Sep 29.
3
The coronavirus is mutating - does it matter?新冠病毒正在变异——这有关系吗?
Nature. 2020 Sep;585(7824):174-177. doi: 10.1038/d41586-020-02544-6.
4
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia.两种配方的基于 rAd26 和 rAd5 载体的异源初免-加强型 COVID-19 疫苗的安全性和免疫原性:来自俄罗斯的两项开放、非随机的 1/2 期研究。
Lancet. 2020 Sep 26;396(10255):887-897. doi: 10.1016/S0140-6736(20)31866-3. Epub 2020 Sep 4.
5
Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine.SARS-CoV-2 重组刺突蛋白纳米颗粒疫苗的 1/2 期临床试验。
N Engl J Med. 2020 Dec 10;383(24):2320-2332. doi: 10.1056/NEJMoa2026920. Epub 2020 Sep 2.
6
ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques.ChAdOx1 nCoV-19 疫苗可预防恒河猴的 SARS-CoV-2 肺炎。
Nature. 2020 Oct;586(7830):578-582. doi: 10.1038/s41586-020-2608-y. Epub 2020 Jul 30.
7
Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques.单次接种 Ad26 疫苗可预防恒河猴感染 SARS-CoV-2。
Nature. 2020 Oct;586(7830):583-588. doi: 10.1038/s41586-020-2607-z. Epub 2020 Jul 30.
8
Developing a low-cost and accessible COVID-19 vaccine for global health.为全球健康研发一种低成本且易于获取的新冠疫苗。
PLoS Negl Trop Dis. 2020 Jul 29;14(7):e0008548. doi: 10.1371/journal.pntd.0008548. eCollection 2020 Jul.
9
A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS.通用设计的贝塔冠状病毒疫苗,用于预防 COVID-19、MERS 和 SARS。
Cell. 2020 Aug 6;182(3):722-733.e11. doi: 10.1016/j.cell.2020.06.035. Epub 2020 Jun 28.
10
Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals.COVID-19 疾病患者和未接触者体内针对 SARS-CoV-2 冠状病毒的 T 细胞反应的靶标。
Cell. 2020 Jun 25;181(7):1489-1501.e15. doi: 10.1016/j.cell.2020.05.015. Epub 2020 May 20.

新冠疫苗:全球挑战与前景论坛建议

COVID-19 vaccines: Global challenges and prospects forum recommendations.

作者信息

Boudjelal Mohamed, Almajed Faisal, Salman Ahmed M, Alharbi Naif K, Colangelo Margaretta, Michelotti Julia M, Olinger Gene, Baker Mariwan, Hill Adrian V S, Alaskar Ahmed

机构信息

King Abdullah International Medical Research Centre, King Saud Bin Abdulaziz University for Health Sciences, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia.

King Abdullah International Medical Research Centre, King Saud Bin Abdulaziz University for Health Sciences, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia.

出版信息

Int J Infect Dis. 2021 Apr;105:448-451. doi: 10.1016/j.ijid.2021.02.093. Epub 2021 Feb 27.

DOI:10.1016/j.ijid.2021.02.093
PMID:33652065
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7912554/
Abstract

The 11th KAIMRC Annual Research Forum Themed "COVID-19 Vaccine: Global Challenges and Prospects Forum" discussed COVID19 Vaccines. The Forum was a vital event as it provided a hub for leading COVID-19 vaccine scientists, regulators, developers, and distributors to learn about COVID-19 vaccines in development, make decisions about the best vaccines to use, and develop appropriate plans for global distribution and pricing. The COVID-19: Global Efforts for Development, Clinical Trials and Distribution Symposium brought together leading scientists, clinicians, pharma, decision makers, academic institutions and businesses to present and discuss the vaccines that are being currently developed for the COVID19. This event was held to shed light on these vaccines as many are at the late stage of Phase III clinical trials and ready to be marketed. This follows the confusion that few vaccines were produced and pushed into phase III without sharing all the necessary data preventing the scientific and clinical community to judge its efficacy and safety. This event allowed a discussion into the challenges in the distribution, pricing and accessibility of the vaccines. Moreover, the symposium discussed the importance to invest in Biotech-Pharma to combat and overcome any future health crisis. The discussion focused on Saudi Arabia leading initiatives as front runner in the field among G20 members.

摘要

第十一届沙特国王阿卜杜勒阿齐兹城科学研究中心年度研究论坛以“新冠疫苗:全球挑战与前景论坛”为主题,对新冠疫苗展开了讨论。该论坛是一项重要活动,它为新冠疫苗领域的顶尖科学家、监管机构、研发人员及经销商提供了一个平台,使他们能够了解正在研发的新冠疫苗,决定使用最佳疫苗,并制定全球分发与定价的适当计划。“新冠疫情:全球研发、临床试验及分发努力”研讨会汇聚了顶尖科学家、临床医生、制药企业、决策者、学术机构及企业,以展示并讨论目前正在研发的针对新冠病毒的疫苗。举办此次活动是为了阐明这些疫苗的情况,因为许多疫苗正处于三期临床试验后期并即将上市。此前曾出现混乱局面,少数疫苗在未共享所有必要数据的情况下就进入三期临床试验,这使得科学界和临床界无法评判其疗效和安全性。此次活动对疫苗分发、定价及可及性方面的挑战进行了讨论。此外,研讨会还讨论了投资生物技术制药企业以应对和克服未来任何健康危机的重要性。讨论聚焦于沙特阿拉伯在二十国集团成员中作为该领域领跑者所引领的各项举措。